Victor Youssef Yazbeck MD , MS

PubMed

• Feasibility and preliminary efficacy of a physical activity intervention in adults with lymphoma undergoing treatment.
  Juliana V Costa, Alexander R Lucas, Shannon L Mihalko, Peter H Brubaker, Alexandra Marshall
  Pilot and Feasibility Studies. 2025-01-14
• New and developing first line pharmacotherapies for treating non-Hodgkin lymphoma.
  Bruce Hough, Olga Lytvynova, Ariel Sindel, Patrick Willard, Victor Yazbeck
  Expert Opinion on Pharmacotherapy. 2024-08-01
• 1 citations
  Advances in Hodgkin's lymphoma pharmacotherapy: a focus on histone deacetylase inhibitors.
  Thuy Ho, Cara Coleman, Palak Shah, Victor Yazbeck
  Expert Opinion on Pharmacotherapy. 2023-06-02

Abstracts/Posters

• Phase 2 Study of Frontline Brentuximab Vedotin Plus Nivolumab in Patients with Hodgkin Lymphoma Aged _60 YearsClinically Relevant Abstract
  Victor Yazbeck, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Brentuximab Vedotin in Front-Line Therapy of Hodgkin Lymphoma (HL) and CD30-Expressing Peripheral T-Cell Lymphoma (PTCL) in Adults Age 60 and Above
  Victor Yazbeck, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Primary Ocular Lymphoma: A SEER Database Analysis of Patterns of Involvement and Outcomes
  Victor Yazbeck, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019